In recent years, inhibitors of the programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) have shown strong anti-tumor activity and become standard anti-tumor treatments for patients with lung cancer (5). This evidence concerns the gene CD274 and lung cancer.